Recent

% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

  • stockmarket1967 stockmarket1967 Aug 6, 2013 8:58 PM Flag

    Bristol Meyers hiring hundreds of Diabetes Sales reps. Posted today on BMY website today!

    Do they have a new diabetes drug?

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I still think Bristol Meyers and Astra Zeneca have to at least think about Mannkind if they want to expand theor diabetes platform.

      Sentiment: Strong Buy

    • Reposting since its been brought up again!

      Sentiment: Strong Buy

    • I noticed that too. Either they see Afrezza as a huge threat and are pulling out all stops to defend their turf, or they are recruiting a huge field force for a new partnership. If it were for a partnership with Afrezza, however, I wonder about the timing. It takes a huge amount of time to gear up production for a new drug, develop/produce packaging, etc. etc. Would they begin hiring a field force now? Possibly I guess - it could require a great deal of upfront training given the new drug delivery system. We shall see. If either of these scenarios are legit, then either would be a good harbinger of positive Afrezza clinicals.

    • great find, first interesting and relevant post from Yahoo board in a while, rest are garbage opinions

    • Did you see this: BMS to put more sales oomph behind Eliquis, diabetes?? July 25 2013.

      Sentiment: Strong Buy

    • I still believe this partnership of Bristol Meyers and Astra Zeneca might be a potential partner/ take over for Mankind! If any company was looking for the newest technology and expanding their diabetes product line. I know i would be looking at Mankind! just a thought?

      Sentiment: Strong Buy

    • this seems to be the piece everyone is asking about?

      Thursday, July 25, 2013 5:00 pm EDT

      WILMINGTON, Del. & PRINCETON, N.J.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission for investigational drug dapagliflozin
      Thursday, July 25, 2013 5:00 pm EDT

      WILMINGTON, Del. & PRINCETON, N.J.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission for investigational drug dapagliflozin for the treatment of adults with type 2 diabetes. The FDA assigned a new Prescription Drug User Fee Act (PDUFA) goal date of Jan. 11, 2014.

    • I still find this whole thing interesting. Would mnkd make a good fit with bristol and astra?

    • YES---they do.... so we have to consider this without any excitement:
      ________________________
      Bydureon, acquired in the Amylin deal, also came in below estimates. Analysts had projected $84 million in sales. The drug’s revenue was $66 million, Bristol-Myers said.

      “Clearly, the diabetes market has become increasingly competitive,” Bancroft said. “We, along with our partner AstraZeneca, recognize the need for adequate resources in this business and to execute better to drive growth. Therefore, we plan to increase our commercial investment in the second half of the year.” London-based AstraZeneca Plc (AZN) splits promotion of some of Bristol-Myers’s diabetes products.

      Second-quarter earnings of 44 cents matched the average of 17 analysts’ estimates compiled by Bloomberg. Net income fell 17 percent to $536 million, or 32 cents, from $645 million, or 38 cents, a year earlier, the company said in a statement

    • Interesting that BMY laid off 479 pharma reps back on 11/06/12. I wonder what brand new diabetes blockbuster they are gearing up to promote with this massive nation wide hiring?

      Hmmm...!

      Sentiment: Strong Buy

    • View More Messages
 
MNKD
1.16-0.02(-1.69%)Jun 30 4:00 PMEDT